RecruitingNot ApplicableNCT06974994

Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation

Resilience to Antibiotic-induced Obesogenic Microbiota Vertically Transferred to the Neonatal Gut: Discovering Mechanism of Microbiota Modulation


Sponsor

Turku University Hospital

Enrollment

125 participants

Start Date

May 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.


Eligibility

Min Age: 2 Hours

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Synbiotic Supplement for people with healthy newborn infants. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Hours and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTSynbiotic Supplement

Bifidobacterium bifidum and human milk oligosaccharides (HMOs)

OTHERPlacebo

Maltodextrin


Locations(1)

Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku

Turku, Valitse Maakunta., Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06974994